Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
BRCA1 Mutation: early-phase trial registry
10 of 16 indexed BRCA1 Mutation trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,060 of 28,707 conditions by registered trial count.
16 US clinical trials · 10 currently recruiting · #1,060 of 28,707 conditions by registered trial count
BRCA1 Mutation: 16 US clinical trials tracked, 10 recruiting.
BRCA1 Mutation is the subject of 16 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is Abramson Cancer Center at Penn Medicine, running 2 of these trials.
Enrollment posture brief
Registry condition brca1-mutation
OPEN 10 | RECR 63% | LATE 1 | EARLY 7 | RANK #1060 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Advanced Gastroesophageal Junction Adenocarcinoma (63% recruiting · 8 trials)
BRCA1 Mutation lists 10 open slots (63% of 16 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for BRCA1 Mutation on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
BRCA1 Mutation is recruiting above its size-band peers.
10 of 16 indexed trials (62.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of BRCA1 Mutation trials is spread across many organizations.
Abramson Cancer Center at Penn Medicine accounts for 2 of 16 trials (12.5%). 14 distinct sponsors appear on at least one study for this condition label.
-
Typical BRCA1 Mutation enrolment sits around 100 participants.
Median target enrolment is 100 among the 16 trials that report a genuine target (sentinel values excluded). 8 of those (50%) plan for fewer than 100 participants.
-
BRCA1 Mutation research is mostly interventional.
12 interventional and 4 observational studies make up this index (75% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
16 total, page 1 of 1
An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results
Memorial Sloan Kettering Cancer Center
NCT05420064
FaCT Trial (Facilitated Cascade Testing Trial)
Weill Medical College of Cornell University
NCT04613440
Prostate Cancer Genetic Risk Evaluation and Screening Study
Massachusetts General Hospital
NCT05129605
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
858 Therapeutics
NCT06395519
Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy
Duke University
NCT06972719
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations
Rana McKay, MD
NCT05498272
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
General Oncology
NCT04150042
Combination Therapy in Cancers With Mutations in DNA Repair Genes
University of California, San Francisco
NCT05694715
Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer
Dana-Farber Cancer Institute
NCT06488378
Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors
Pamela Munster
NCT06177171
BRCA Founder OutReach (BFOR) Study
Memorial Sloan Kettering Cancer Center
NCT03351803
Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation
Alliance for Clinical Trials in Oncology
NCT04711109
Evaluating Cascade Communication Methods
University of Pennsylvania
NCT04428736
BRCA1/2 Flu Vaccine
Abramson Cancer Center at Penn Medicine
NCT04499534
Decision Support for BRCA Testing in Ethnically Diverse Women
Columbia University
NCT03470402
HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer
Abramson Cancer Center at Penn Medicine
NCT03685331
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on BRCA1 Mutation records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on BRCA1 Mutation trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this BRCA1 Mutation page
16 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 10 BRCA1 Mutation trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Abramson Cancer Center at Penn Medicine sponsors the most BRCA1 Mutation trials on record, review their full trial history before evaluating a specific study. See Abramson Cancer Center at Penn Medicine's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This BRCA1 Mutation condition card totals 16 registered trials; most-linked intervention Olaparib; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.